~ Buy the ILLUCCIX (gallium ga-68 gozetotide) Drug Profile, 2024 PDF Report in the Report Store ~

ILLUCCIX Drug Patent Profile

Which patents cover Illuccix, and when can generic versions of Illuccix launch?

Illuccix is a drug marketed by Telix and is included in one NDA. There is one patent protecting this drug.

This drug has forty-two patent family members in eighteen countries.

The generic ingredient in ILLUCCIX is gallium ga-68 gozetotide. There are sixteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the gallium ga-68 gozetotide profile page.

DrugPatentWatch^® Generic Entry Outlook for Illuccix

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 28, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ILLUCCIX

International Patents:	42
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
Drug Prices:	Drug price information for ILLUCCIX
What excipients (inactive ingredients) are in ILLUCCIX?	ILLUCCIX excipients list
DailyMed Link:	ILLUCCIX at DailyMed

See drug prices for ILLUCCIX

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ILLUCCIX

NDA:

214032

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ILLUCCIX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Telix International Pty Ltd	Phase 3
Grand Pharmaceutical (China) Co., Ltd.	Phase 3
BAMF Health	Early Phase 1

See all ILLUCCIX clinical trials

US Patents and Regulatory Information for ILLUCCIX

ILLUCCIX is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ILLUCCIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Telix	ILLUCCIX	gallium ga-68 gozetotide	POWDER;INTRAVENOUS	214032-001	Dec 17, 2021		RX	Yes	Yes

International Patents for ILLUCCIX

When does loss-of-exclusivity occur for ILLUCCIX?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Belgium

Brazil

Canada

China

Denmark

European Patent Office

Hungary

Israel

Japan

Mexico

New Zealand

Poland

Portugal

Russian Federation

South Africa

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ILLUCCIX around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2724894	НАБОР ДЛЯ МЕЧЕНИЯ РАДИОАКТИВНЫМИ ИЗОТОПАМИ (RADIO-ISOTOPE LABELING KIT)
Mexico	2017002361	MONO-, DI-, O POLISACARIDO USADO COMO INHIBIDOR DE METAL EN LA PREPARACION DEL AGENTE ENFOCADO FUNCIONALIZADO CON QUELATO GALIO 68 (68GA). (MONO-, DI- OR POLYSACCHARIDE USED AS METAL INHIBITOR IN THE PREPARATION OF 68GA-CHELATE-FUNCTIONALIZED TARGETING AGENT.)
Portugal	3185911
Mexico	2017002362	KIT PARA MARCAJE RADIACTIVO CON GALIO 68 (68GA) QUE COMPRENDE UN INHIBIDOR DE METAL. (KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR.)
Australia	2015309187	Kit for radiolabelling with 68GA comprising a metal inhibitor
China	106659806	在制备68GA‑螯合物官能化的靶向剂中用作金属抑制剂的单糖、二糖或多糖 (Mono-, di- or polysaccharide used as metal inhibitor in the preparation of 68GA-chelate-functionalized targeting agent)